NCT07330440Enrolling By Invitation1 期
A Phase I, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) in Healthy Participants Aged 18-55 Years, Stratified by Serostatus
干预措施
试验速览
- 阶段
- 1 期
- 状态
- Enrolling By Invitation
- 入组人数
- 144
- 试验地点
- 1
- 主要终点
- Safety Endpoints
研究概览
简要总结
A Preliminary Evaluation of the Safety and Immunogenicity Post-Vaccination with Different Doses of an mRNA Vaccine against Herpes Simplex Virus Type 2 (HSV-2) in Populations with Different Serostatus
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Is a healthy male or female aged 18 to 55 years (inclusive) at the time of screening.
- •Has provided written informed consent prior to performing any study-specific procedure.
- •Is available and willing to comply with all study procedures for the entire duration of the study.
- •For participants of childbearing potential: agrees to practice highly effective contraception for the required period and has no plans for reproduction or gamete donation.
- •Provides consent for HSV-1/HSV-2 serology testing at screening.
排除标准
- •Axillary temperature >37.0°C during screening and/or on the day of vaccination.
- •History of clinically diagnosed genital herpes within 6 months prior to the first vaccination.
- •Acute infectious disease or acute exacerbation of a chronic condition within 3 days prior to screening/vaccination.
- •Positive blood pregnancy test at screening or currently breastfeeding (for female participants).
- •History of severe allergic reactions requiring medical intervention (e.g., anaphylaxis, angioedema, Arthus reaction, allergic purpura), severe adverse reactions to previous vaccinations, or known hypersensitivity to any component of the investigational vaccine (e.g., lipid nanoparticles).
- •Known or suspected malignancy, autoimmune disease, immunodeficiency, organ transplantation, or immunosuppression (e.g., HIV infection, systemic lupus erythematosus [SLE], rheumatoid arthritis).
- •Use of immunosuppressants or immunomodulators (e.g., systemic corticosteroids for >14 consecutive days) or cytotoxic therapy within 6 months prior to the first vaccination, or planned use during the study.
- •Congenital anomalies or developmental disorders affecting organ function.
- •History of cardiovascular diseases (e.g., myocardial ischemia, myocardial infarction, myocarditis, pericarditis, idiopathic cardiomyopathy, arrhythmias), or any condition increasing the risk of myocarditis/pericarditis; QTcF >450 ms for males or >470 ms for females; or uncontrolled hypertension (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg despite medication).
- •For HSV-1/HSV-2 seronegative participants: clinically significant abnormalities in hematology, blood biochemistry, coagulation, or urinalysis parameters at screening.
- •For HSV-1/HSV-2 seropositive participants: hematology, blood biochemistry, coagulation, or urinalysis parameters ≥ Grade 1 per the study-specific toxicity grading scale and deemed clinically significant by the investigator.
- •Contraindications to intramuscular injection (e.g., thrombocytopenia, coagulation disorders).
- •Medical conditions requiring intervention affecting the endocrine, hematologic, hepatic, renal, respiratory, metabolic, or skeletal systems.
- •History of convulsions (excluding febrile seizures in childhood), epilepsy, encephalopathy, psychiatric disorders, or other neurological conditions; or family history of psychiatric disorders.
- •Positive markers for HBV, HCV, HIV, or syphilis infection.
- •Administration of blood products or immunoglobulins within 3 months prior to the first vaccination or planned use during the study.
- •Treatment with anti-herpetic drugs (e.g., acyclovir, valacyclovir, famciclovir, ganciclovir) for genital herpes within 6 months prior to the first vaccination.
- •Receipt of live-attenuated vaccines within 14 days, or subunit/inactivated vaccines within 7 days prior to vaccination.
- •Participation in another clinical trial (drug, device, or vaccine) within 3 months prior to the first vaccination or concurrent enrollment in any interventional study.
- •Any other condition deemed by the investigator to compromise participant safety or interfere with study objectives.
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo Group (Biological)
Low-Dose
Experimental
HSV-2 mRNA Vaccine
干预措施: Low-Dose Cohort (Biological)
Mid-Dose
Experimental
HSV-2 mRNA Vaccine
干预措施: Mid-Dose Cohort (Biological)
High-Dose
Experimental
HSV-2 mRNA Vaccine
干预措施: High-Dose Cohort (Biological)
结局指标
主要结局
Safety Endpoints
时间窗: Up to 30 days after each dose
Incidence of Adverse Events within 30 Days After Each Vaccination
次要结局
- Safety Endpoints(up to 14 days)
- Safety Endpoints(from Day 0 up to 540 days)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or AboveNCT07285278Suzhou Abogen Biosciences Co., Ltd.300
进行中（未招募）
2 期
Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or AboveNCT07289542Suzhou Abogen Biosciences Co., Ltd.420
已完成
2 期
Immunogenicity of licensed MF59 adjuvanted Influenza and SARS-CoV-2 vaccine combinations for Older Adults (ISOLDA)2024-514798-23-00Cr2o B.V.120
招募中
2 期
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in InfantsNCT07286370GlaxoSmithKline537
进行中（未招募）
1 期
Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older AdultsNCT07295028Sanofi240